Silkworm chrysalis protein immunomodulatory peptide with high immunocompetence as well as preparation method and application thereof
Through the protease hydrolysis and purification technology of silkworm pupa protein, immune-active peptides were screened, which solved the problem of insufficient research on the immunomodulatory peptide of silkworm pupa protein, achieved efficient utilization of silkworm pupa protein, promoted the proliferation and phagocytosis of macrophages, and promoted function Food and drug development.
Patent Information
- Application Number
- CN202411218236.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-08-30
AI Technical Summary
In the prior art, there are few studies on the immunomodulatory peptides of silkworm pupa proteins, and there is a lack of effective preparation methods and applications, which limits the high-value utilization of silkworm pupa proteins.
Through different proteases hydrolyzing silkworm pupa protein, combined with NO generation, macrophage proliferation and phagocytosis experiments, the immunomodulatory peptide of silkworm pupa protein with excellent immunomodulatory activity was screened and identified, and purified by alkaline protease hydrolysis, ultrafiltration and gel chromatography. Technology prepares immunomodulatory peptides with immunoactivity of silkworm pupa proteins.
It effectively promotes the proliferation and phagocytosis of macrophages, significantly improves immune activity, provides a high-value utilization pathway for silkworm pupa protein, and provides new ideas for the development of functional foods and drugs.
Smart Images

Figure CN119060131A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and specifically relates to a silkworm pupa protein immunomodulatory peptide with high immunoactivity and a preparation method and application thereof. Background Art
[0002] Silkworm pupae are byproducts of silk reeling, rich in vitamins, carbohydrates, fats and other nutrients. Silkworm pupae have a high protein content, with a crude protein content of about 48-60%. They are a nutritious source of high-quality protein and a natural insect with important development value. Studies have confirmed that silkworm pupae have multiple uses and values: 1) Relieve fatigue and promote fat metabolism; 2) Antibacterial and anti-inflammatory, can inhibit Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa; 3) As a traditional Chinese medicine, it has the effects of promoting fluid production and quenching thirst, digesting food and regulating qi, and can be used to treat symptoms such as thirst, excessive urination, and swelling; 4) Adjust the body's sugar and fat metabolism, and have significant effects on the treatment of hypercholesterolemia and improving liver function; 5) Broad-spectrum immune substances extracted from silkworm pupae are effective for cancer, arteriosclerosis, hepatitis, nephritis, etc.; 6) Silkworm pupa oil has a certain effect on hypertension, cholesterol, fatty liver, hyperlipidemia, etc.; 7) Diet therapy, silkworm pupae are suitable for patients with hypertension, hyperlipidemia, diabetes, as well as patients with tuberculosis, weak body, malnutrition in children, chronic gastritis, gastroptosis, etc. In China, due to silk harvesting, more than 300,000 tons of silkworm pupae are produced each year. Most silkworm pupae are used as animal feed or fertilizer, and a small part is used as medicinal materials or eaten by people, and their value is not fully utilized. Therefore, it is necessary to explore new ways to utilize silkworm pupae as resources and promote their high-value utilization.
[0003] Bioactive peptides are multifunctional compounds derived from proteins, consisting of 2-20 amino acids, which are released by enzymatic hydrolysis, fermentation, and gastrointestinal digestion. Immunomodulatory peptides are a class of bioactive peptides that have the function of regulating the human immune system. They play an important role in the host defense mechanism by regulating immune cell function, antibody synthesis, and cytokine secretion. In recent years, many studies have shown that immunomodulatory peptides extracted from food proteins are easily absorbed, safe, and relatively cheap for human health consumption. For example, He Ping et al. isolated and purified immunoactive peptides from duck egg ovalbumin and shrimp heads of Penaeus vannamei, respectively, which can significantly enhance the phagocytosis of macrophages and promote the secretion of immune factors such as NO, TNF-α, and IL-6 by macrophages. Lu-Sheng hsiehlu isolated and purified immunoactive peptides from soy protein hydrolysate, which can significantly increase the phagocytic activity of mouse spleen macrophages and neutrophils. Although some studies have reported the immunomodulatory activity of peptides, little information is still known about the structure-activity relationship of peptides.
[0004] Some researchers have isolated and purified bioactive peptides with multiple beneficial effects from silkworm pupa protein. For example, Maria Cerme studied the antioxidant activity of silkworm pupa protein hydrolysate through in vitro antioxidant experiments and in situ reduction of reactive oxygen species (ROS) in liver HepG2, and identified that two peptides showed the highest antioxidant activity in HepG2 cells, including ROS reduction, superoxide dismutase expression, and glutathione production activity. Sun Hee Lee conducted an in vitro mechanism study, stimulated the differentiation and maturation of 3T3-L1 preadipocytes with insulin, evaluated the effects of silkworm pupae and silkworm pupa protein (SPP) on the adipogenesis of mature adipocytes, and found that SP and SPP inhibited preadipocyte differentiation and adipogenesis by regulating signal transduction pathways, and improved obesity by reducing lipid accumulation and adipocyte size. Li Xiaotong found that silkworm pupa protein hydrolysate specifically inhibited the growth of SGC-7901 cells through intrinsic apoptosis pathways, ROS accumulation, and cell cycle arrest through flow cytometry, reactive oxygen content determination, and mitochondrial membrane potential detection. Zhou Yaxi verified the therapeutic effect of SPP on colorectal cancer mice in vivo by subcutaneous tumor creation, confirming that the anti-tumor activity of SPP may be achieved by reducing tumor inflammation, inhibiting tumor proliferation and metastasis, and inducing tumor cell apoptosis.
[0005] At present, there are relatively few studies on silkworm pupa protein immunomodulatory peptides in the art, and only a few documents or patents have reported on them. For example, patent CN115232851A discloses a method for preparing silkworm pupa immune peptides, which uses acidic protease to enzymatically hydrolyze silkworm pupae to obtain silkworm pupa immune peptides with both antibacterial and antioxidant activities. Therefore, it is necessary to study silkworm pupa protein immunomodulatory peptides and their preparation methods, which is of great significance for determining the comprehensive effects of active substances in silkworm pupa protein on immune cells. Summary of the invention
[0006] In view of this, the present invention has carried out in-depth research on silkworm pupa protein immunomodulatory peptides and their extraction process, and screened and identified potential immunomodulatory peptides by using different proteases to hydrolyze silkworm pupa protein, combined with NO generation, macrophage proliferation and phagocytosis experiments. The present invention effectively broadens the utilization rate of silkworm pupa protein peptides and provides a theoretical basis for the further processing and utilization of silkworm pupa protein.
[0007] One of the purposes of the present invention is to provide a silkworm pupa protein immunomodulatory peptide having excellent immune activity.
[0008] To achieve the above object, the present invention adopts the following technical solutions:
[0009] A silkworm pupa protein immunoregulatory peptide, wherein the silkworm pupa protein immunoregulatory peptide contains the amino acid sequence shown in SEQ ID NO.2, SEQ ID NO.3 and / or SEQ ID NO.8.
[0010] Furthermore, the amino acid sequence of the silkworm pupa protein immunomodulatory peptide is shown as SEQ ID NO.2, SEQ ID NO.3 or SEQ ID NO.8.
[0011] The second object of the present invention is to provide a method for preparing silkworm pupa protein immunomodulatory peptide.
[0012] To achieve the above object, the present invention adopts the following technical solutions:
[0013] The preparation method of silkworm pupa protein immunomodulatory peptide comprises the following steps:
[0014] (1) Using defatted silkworm pupa powder as raw material to prepare silkworm pupa protein;
[0015] (2) hydrolyzing the silkworm pupa protein obtained in step (1) with alkaline protease to obtain silkworm pupa protein hydrolysate;
[0016] (3) The silkworm pupa protein hydrolysate obtained in step (2) is separated and purified by ultrafiltration and gel filtration to obtain a separated product;
[0017] (4) performing LC-MS / MS sequencing on the separated product obtained in step (3) to obtain the silkworm pupa protein immunomodulatory peptide.
[0018] Further, step (1) is specifically as follows:
[0019] After defatted silkworm pupa powder is dispersed, stirred and centrifuged, the supernatant is collected; the pH is adjusted to 4.5 with HCL to precipitate protein for 1 hour, and the supernatant is discarded after centrifugation; the precipitate is washed three times with distilled water, adjusted to neutral with NaOH, and vacuum freeze-dried to obtain silkworm pupa protein;
[0020] Preferably, the dispersant of the defatted silkworm pupa powder is 0.5% NaOH.
[0021] Preferably, defatted silkworm pupa powder and 0.5% NaOH are dispersed in a solid-liquid ratio of 1:20.
[0022] Preferably, the agitated centrifugation is carried out by stirring at 40°C for 1 hour and then centrifuging at 1000 g for 15 minutes.
[0023] Preferably, the concentration of HCL is 1M.
[0024] Preferably, the second centrifugation is performed at 3220 g for 15 minutes.
[0025] Preferably, the concentration of NaOH used for neutralization is 0.1M.
[0026] Further, in step (2), first, the silkworm pupa protein powder obtained in step (1) is formulated into a suspension of 10 mg / mL, ultrasonically dissolved at 30 °C for 30 min, and then enzymatically hydrolyzed.
[0027] Further, in step (2), the conditions for enzymatic hydrolysis are as follows: pH is 7 - 9, temperature is 40 °C - 60 °C, and time is 2 h - 5 h; more preferably, pH is 8, temperature is 50 °C, and time is 180 min.
[0028] Further, in step (2), the dosage of the alkaline protease is 5000 U / g - 10000 U / g, and more preferably 6000 U / g.
[0029] Further, in step (2), NaOH is continuously added during the hydrolysis process to maintain the pH.
[0030] Further, in step (2), after the enzymatic hydrolysis reaction ends, it is immediately heated to 90 °C for 10 min for inactivation, cooled to room temperature, the pH is adjusted to 4.5, allowed to stand at room temperature for 30 min, and centrifuged at 3220 g for 15 min; the pH of the enzymatic hydrolysate is adjusted to neutral, and after freeze-drying, the silkworm pupa protein hydrolysate is obtained.
[0031] Further, in step (3), the ultrafiltration includes: diluting the silkworm pupa protein hydrolysate with distilled water and separating it into fractions with molecular weight cut-off values of 10 kDa and 3 kDa using an ultrafiltration membrane; the hydrolysis products are divided into three fractions: SPPH-A-I (MW > 10 kDa), SPPH-A-II (10 kDa < MW < 3 kDa), and SPPH-A-III (MW < 3 kDa), and the ultrafiltration product is obtained.
[0032] Further, in step (3), the gel filtration purification is to separate and purify the fraction with the strongest immunomodulatory activity after ultrafiltration by G-25 gel filtration chromatography; chromatographic purification is carried out using an AKTApuro instrument, the sample concentration is 10 mg / mL, eluted with ultrapure water at 1 mL / min, and the absorbance is measured at 280 nm to obtain the separated product.
[0033] Preferably, the G-25 gel filtration chromatography uses a Sephadex G-25 packed size exclusion chromatography column with a column size of 1.6 cm × 100 cm.
[0034] Further, for the LC-MS / MS, the liquid phase uses a C18 chromatographic column, with formic acid aqueous solution as mobile phase A and formic acid acetonitrile aqueous solution as mobile phase B, and separation is carried out by gradient elution; after separation, it is analyzed using a mass spectrometer; the gradient elution program is set as follows:
[0035] From 0 min to 50 min, a linear gradient where mobile phase B ranges from 4% to 50% and mobile phase A ranges from 96% to 50%.
[0036] 50 min-54 min, linear gradient from 50% to 100% mobile phase B and from 50% to 0% mobile phase A;
[0037] 54min-60min, liquid B remains at 100%.
[0038] Preferably, the separated product is desalted and then used for mass spectrometry detection.
[0039] Preferably, the chromatographic column adopts RP-C18, column Technology Inc., with a specification of 0.15mm*150mm.
[0040] Preferably, the mobile phase A is 0.1% formic acid aqueous solution.
[0041] Preferably, the mobile phase B is a 0.1% formic acid-acetonitrile aqueous solution, wherein the acetonitrile content is 84%.
[0042] Preferably, the liquid chromatography column is equilibrated with 95% liquid A.
[0043] Preferably, capillary high performance liquid chromatography is used for separation, and Q Exactive HF-X mass spectrometer mass spectrometry analysis is performed, with an analysis time of 60 minutes and a positive ion detection mode.
[0044] The third object of the present invention is to provide an application of the aforementioned silkworm pupa protein immunoregulatory peptide in the preparation of a product that enhances the body's immune regulation.
[0045] To achieve the above object, the present invention adopts the following technical solutions:
[0046] The application of the aforementioned silkworm pupa protein immunomodulatory peptide in the preparation of products for enhancing body immunity.
[0047] Furthermore, the product includes any one or more of functional food, dietary supplement, medicine, skin care product, and cosmetics.
[0048] The fourth object of the present invention is to provide an application of the aforementioned silkworm pupa protein immunomodulatory peptide in the preparation of a promoter for promoting macrophage proliferation, phagocytosis and / or NO production.
[0049] The beneficial effects of the present invention are:
[0050] 1. The three silkworm pupa protein immunoregulatory peptides provided by the present invention can effectively promote the proliferation and phagocytosis of macrophages and have good immune activity.
[0051] 2. The present invention provides a method for preparing a silkworm pupa protein immunomodulatory peptide. The present invention first compares the effects of different proteases hydrolyzing silkworm pupa protein, and finally selects an alkaline protease with a high degree of hydrolysis to hydrolyze silkworm pupa protein. Potential immunomodulatory peptides were screened and identified through NO generation, macrophage proliferation and phagocytosis experiments. Then, three potential immunoactive peptides were screened out by LC-MS / MS sequencing combined with molecular docking. Studies have confirmed that the bioactive peptides extracted from silkworm pupa protein hydrolyzed by alkaline protease have a good immunomodulatory effect on RAW264.7 cells, and can promote the proliferation, NO production and phagocytosis of RAW264.7 cells. They mediate immune activation through hydrogen bonds and hydrophobic interactions with TLR2 and TLR4 / MD-2. The silkworm pupa protein immunomodulatory peptides and their preparation methods provided by the present invention provide a strategic basis for the identification of the biological activity of silkworm pupa protein peptides, and provide new ideas for the application of silkworm pupa protein peptides as functional food ingredients. BRIEF DESCRIPTION OF THE DRAWINGS
[0052] Figure 1 It is the measurement result diagram of DH;
[0053] Figure 2 It is a statistical diagram of the ratio of the secondary structure content of SPP to each separated and purified product;
[0054] Figure 3 This is the mass spectrum of silkworm pupa protein immunoreactive peptide Peptide 1;
[0055] Figure 4 This is the mass spectrum of silkworm pupa protein immunoreactive peptide Peptide 2;
[0056] Figure 5 This is the mass spectrum of silkworm pupa protein immunoreactive peptide Peptide 3;
[0057] Figure 6 This is the mass spectrum of silkworm pupa protein immunoreactive peptide Peptide 4;
[0058] Figure 7 This is the mass spectrum of silkworm pupa protein immunoreactive peptide Peptide 5;
[0059] Figure 8 This is the mass spectrum of silkworm pupa protein immunoreactive peptide Peptide 6;
[0060] Fig. 9 This is the mass spectrum of silkworm pupa protein immunoreactive peptide Peptide 7;
[0061] Fig.10 This is the mass spectrum of silkworm pupa protein immunoreactive peptide Peptide 8;
[0062] Fig.11This is the mass spectrum of silkworm pupa protein immunoreactive peptide Peptide 9;
[0063] Fig.12 The figure is a molecular interaction diagram of peptide 3, peptide 2 and peptide 8 binding to TLR2 and TLR4 / MD-2, wherein: Fig.12 -A is a diagram of the molecular interaction between Peptide 3 and TLR2 (PDB: ID: 1FYW), Fig.12 -B is a diagram of the molecular interaction between Peptide 2 and TLR2 (PDB: ID: 1FYW), Fig.12 -C is a diagram of the molecular interaction between Peptide 8 and TLR2 (PDB: ID: 1FYW), Fig.12 -D is a diagram of the molecular interaction between Peptide 3 and TLR4 / MD-2 (PDB: ID: 5IJD). Fig.12 -E is a diagram of the molecular interaction between Peptide 2 and TLR4 / MD-2 (PDB: ID: 5IJD), Fig.12 -F is a diagram of the molecular interaction of peptide 8 binding to TLR4 / MD-2 (PDB: ID: 5IJD);
[0064] Fig.13 The following is a graph showing the test results of the immunological activity of three synthetic peptides, among which: Fig.13 -A is a statistical diagram of the proliferation rate of macrophages treated with different peptides, Fig.13 -B is a statistical diagram of the phagocytic rate of macrophages treated with different peptides;
[0065] Fig.14 The results of the effects of four silkworm pupa protein protease hydrolysates on macrophage immune activity indicators are shown in Figure 2. Fig.14 -A is a graph showing the effects of four enzymatic hydrolysates on macrophage proliferation; Fig.14 -B is the result diagram of the effects of four enzymatic hydrolysis products on NO production in macrophages; Fig.14 -C is the result diagram of the effects of four enzymatic hydrolysis products on macrophage phagocytosis;
[0066] Fig.15 The results of the effects of three ultrafiltration products on the immune activity indicators of macrophages are shown in Figure 2. Fig.15 -A is a graph showing the effects of three ultrafiltration products on macrophage proliferation; Fig.15 -B is the result diagram of the effects of three ultrafiltration products on the NO production of macrophages; Fig.15 -C is a result diagram showing the effects of three ultrafiltration products on macrophage phagocytosis;
[0067] Fig.16The result diagram of the separation and purification of SPPH-A-III by Sephadex G-25;
[0068] Fig.17 The results of the three Sephadex G-25 separation products on the macrophage immune activity indicators are shown in Figure 2. Fig.17 -A is a graph showing the effects of three Sephadex G-25 separation products on macrophage proliferation; Fig.17 -B is a graph showing the effects of three Sephadex G-25 separation products on NO production in macrophages; Fig.17 -C is a graph showing the effects of three Sephadex G-25 separation products on macrophage phagocytosis;
[0069] Fig.18 The figure shows the results of EdU incorporation into RAW264.7 cells after treatment with 200 μg / mL sample solution, and the total number of cells (scale bar = 50 μm) is quantified. Fig.18 -A is the fluorescence image, Fig.18 -B is a positive quantitative result graph.
[0070] In the above figures, asterisks indicate statistically significant differences, * indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001, and ns indicates no statistical significance. DETAILED DESCRIPTION
[0071] The technical solution of the present invention will be further described clearly and completely in conjunction with specific embodiments below. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments. Therefore, based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative work belong to the protection scope of the present invention.
[0072] The immune system regulates various physiological processes in the body. Therefore, improving the body's immunity and enhancing immune function are essential for preventing the occurrence of diseases and restoring health. Macrophages are important cells in the body's immune function and are the body's first line of defense against infection. Activated macrophages participate in immune responses directly or indirectly. They remove foreign antigens, senescent cells and cell debris through phagocytosis, and secrete cytokines such as reactive oxygen, reactive nitrogen, TNF-α, and IL-6 to participate in immune responses. Therefore, macrophages are considered to be an ideal cell model for evaluating the immunomodulatory activity of bioactive compounds. The activation of macrophages is mediated by pattern recognition receptors (PRRs), including mannose receptors (MRs), toll-like receptors (TLRs), scavenger receptors, and complement receptors (CRs). Many substances with immunomodulatory activity activate macrophages by interacting with PRRs. For example, maca protein hydrolysate activates RAW 264.7 cells through NF-κB and MAPK signaling pathways mediated by TLR2 and TLR4 receptors. The TLR family is the most characterized PRR family in mammals. Compared with other PRRs, TLRs are reported to interact with a variety of components, including dietary fiber, lipids, proteins, peptides and nucleic acids. Therefore, in the present embodiment, the immune activity of the polypeptide is detected by detecting the effect of the polypeptide on the immune activity of macrophages.
[0073] In the embodiment of the present invention, the alkaline protease is produced by the selected Bacillus licheniformis, and the main active ingredient is subtilisin A. It is an endoprotease that mainly acts on peptide bonds containing hydrophobic carboxyl groups. Under alkaline conditions, it can effectively decompose proteins into smaller peptides or amino acids. Since this enzyme has a higher activity under alkaline conditions, it is classified as an alkaline protease.
[0074] In the embodiments of the present invention, defatted silkworm pupa powder was purchased from Huzhou Nanxun Zhanhong Silkworm Pupa Processing Factory; trypsin (≥2500U / mg), pepsin (>3000U / mg), flavor enzyme (150U / mg), alkaline proteinase (alcalase, 2000U / mg), o-phthalaldehyde (≥99%), serine (≥99%), DL-dithiothreitol (≥99%), and sodium tetraborate (99.5%) were purchased from Beijing Puxitang Biotechnology Co., Ltd.; lipopolysaccharide (LPS) and CCK8 were obtained from Sigma (USA). Culture medium (DMEM), fetal bovine serum (FBS), penicillin-streptomycin antibody and phosphate-buffered saline (PBS) were purchased from Gibco (USA); NO and neutrophil proliferation kits were purchased from Shanghai Biotechnology Co., Ltd., China; ultrafiltration tubes were purchased from Millipore (MA, USA); CCK8 was purchased from Biotechnology Co., Ltd., China; RAW 264.7 cells were purchased from ATCC (American Type culture Collection, Rockville, MD, USA); BeyClickTMEdU-488 imaging kit was purchased from Sigma, USA; other chemicals and reagents used were of analytical grade.
[0075] In the embodiments of the present invention, the manufacturer of the FTIR-650 spectrometer is Tianjin Guangdong Technology Co., Ltd. (Tianjin, China); the manufacturer of the Zorbax300SB-C18 peptide trap is Agilent Technologies; the manufacturer of the Q Exactive HF-X mass spectrometer is Thermo Fisher; and the manufacturer of the multifunctional microplate reader is SpecteaMax iD5, USA.
[0076] In the embodiment of the present invention, BIOPEP is a database containing protein sequences, bioactive peptides and sensitive peptides, developed by University of Warmia Mazury in Poland, and its webpage is: http: / / www.uwm.edu.pl / biochemia / index.php / en / biopep, accessed.
[0077] In the embodiment of the present invention, the preparation method of silkworm pupa protein immunomodulatory peptide is as follows:
[0078] (1) Preparation of silkworm pupa protein: The defatted silkworm pupa powder was dispersed in 0.5% NaOH at a ratio of 1:20 (solid to liquid). After stirring at 40 °C for 1 hour, it was centrifuged at 1000 g for 15 minutes, and the supernatant was taken. The pH was adjusted to 4.5 with 1M HCl to precipitate the protein for 1 hour, and then centrifuged at 3220 g for 15 minutes. The supernatant was discarded, and the precipitate was washed three times with distilled water, adjusted to neutral with 0.1M NaOH, and freeze-dried under vacuum to obtain silkworm pupa protein;
[0079] (2) Enzymatic hydrolysis of silkworm pupa protein: The silkworm pupa protein powder obtained in step (1) was formulated into a suspension of 10 mg / mL and ultrasonicated at 30 °C for 30 min. 6000 U / g of alkaline protease was added to the silkworm pupa protein suspension for hydrolysis. The optimal hydrolysis conditions were pH = 8, 50 °C, and 180 min. 1M NaOH was continuously added during the hydrolysis process to maintain the pH. After the reaction, it was immediately heated to 90 °C for 10 min to inactivate the enzyme, cooled to room temperature, the pH was adjusted to 4.5, and left standing at room temperature for 30 min, then centrifuged at 3220 g for 15 min. The pH of the enzymatic hydrolysate was adjusted to neutral, and freeze-dried to obtain silkworm pupa protein hydrolysate (SPPH-A).
[0080] (3) Ultrafiltration: The silkworm pupa protein hydrolysate obtained in step (2) was diluted with distilled water and separated by an ultrafiltration membrane into molecular weight cut-off values of 10 kDa and 3 kDa; the hydrolysate was divided into three fractions: SPPH-A-I (MW > 10 kDa), SPPH-A-II (10 kDa < MW < 3 kDa), and SPPH-A-III (MW < 3 kDa); all fractions were collected and freeze-dried to obtain the ultrafiltration product;
[0081] (4) Gel filtration chromatography purification: The fraction with the strongest immunomodulatory activity after ultrafiltration (SPPH-A-III) was separated and purified by G-25 gel filtration chromatography. The column size was 1.6 cm × 100 cm; AKTA puro instrument was used for chromatographic purification. The sample concentration was 10 mg / mL, and eluted with ultrapure water at 1 mL / min. The absorbance was measured at 280 nm, and each elution peak was collected and freeze-dried to obtain the separated products (F1, F2, and F3);
[0082] LC-MS / MS sequencing: The separated products were desalted for mass spectrometry detection; the chromatographic conditions in the liquid phase included: using a C18 chromatographic column (0.15 mm * 150 mm, RP-C18, column Technology Inc.), 0.1% formic acid aqueous solution as mobile phase A, and 0.1% formic acid acetonitrile aqueous solution as mobile phase B. The acetonitrile content in mobile phase B was 84%; the liquid chromatographic column was equilibrated with 95% of solution A; the sample was sent from the autosampler to a Zorbax 300SB-C18 peptide trap and separated on the chromatographic column; the liquid phase gradient was set as follows:
[0083] 0min-50min, linear gradient of mobile phase B from 4% to 50%, mobile phase A from 96% to 50%;
[0084] 50 min-54 min, linear gradient from 50% to 100% of mobile phase B and from 50% to 0% of mobile phase A;
[0085] 54min-60min, liquid B remains at 100%.
[0086] Capillary HPLC separation and mass spectrometry analysis were performed on a Q Exactive HF-X mass spectrometer with an analysis time of 60 min and a positive ion detection mode. The mass-to-charge ratios of peptides and peptide fragments were collected as follows: 10 fragment maps (MS2 scans) were collected after each full scan.
[0087] Example 1. Preparation method of silkworm pupa protein immunomodulatory peptide
[0088] 1. Preparation of Silkworm Pupa Protein
[0089] Disperse defatted silkworm pupa powder in 0.5% NaOH at a ratio of 1:20 to liquid, stir at 40°C for 1 hour, then centrifuge at 1000g for 15 minutes, and take the supernatant. Then adjust the pH to 4.5 with 1M HCL to precipitate protein for 1 hour, and centrifuge again at 3220g for 15 minutes. Discard the supernatant, wash the precipitate three times with distilled water, adjust to neutral with 0.1M NaOH, and vacuum freeze-dry to obtain silkworm pupa protein, which is stored at -20°C for later use.
[0090] 2. Enzymatic hydrolysis of silkworm pupa protein
[0091] The silkworm pupa protein powder obtained in step 1 was prepared into a 10 mg / mL suspension and ultrasonically dissolved at 30°C for 30 minutes; four different proteases were used for hydrolysis, and the optimal hydrolysis conditions were alcalase (pH = 8, 50°C), flavor enzyme (pH = 6.5, 50°C), pepsin (pH = 1.8, 37°C), and trypsin (pH = 7, 37°C). 6000U / g of protease was added to the silkworm pupa protein suspension for hydrolysis for 180 minutes, and 1M NaOH was continuously added during the hydrolysis process to maintain the pH. Immediately after the reaction, it was heated to 90°C for inactivation for 10 minutes, cooled to room temperature, and the pH was adjusted to the isoelectric point of silkworm pupa protein (pH = 4.5), allowed to stand at room temperature for 30 minutes, and centrifuged at 3220g for 15 minutes. The pH of the enzymatic hydrolyzate was adjusted to neutral, and the silkworm pupa protease hydrolyzate was obtained after freeze-drying and stored at -20°C. The four enzymatic hydrolyzates obtained were named SPPH-A, SPPH-F, SPPH-P, and SPPH-T.
[0092] 3. Separation and purification of hydrolyzate
[0093] (1) Ultrafiltration
[0094] The hydrolysate was diluted with distilled water and separated by an ultrafiltration (UF) membrane into molecular weight cut-off (MWCO) values of 10 kDa and 3 kDa. The hydrolysate was divided into three fractions: MW > 10 kDa, 10 kDa < MW < 3 kDa, and MW < 3 kDa. All fractions were collected and freeze-dried for activity verification.
[0095] (2) Gel filtration purification
[0096] The most immunomodulatory active component after ultrafiltration was separated and purified by G-25 gel filtration chromatography. The column size was 1.6 cm × 100 cm. Chromatographic purification was carried out using an AKTA puro instrument. The sample concentration was 10 mg / mL, and it was eluted with ultrapure water at 1 mL / min. The absorbance was measured at 280 nm, and each elution peak was collected and freeze-dried for storage.
[0097] Example 2. Effects of different proteases on DH
[0098] During protein hydrolysis, the percentage of hydrolyzed peptide bonds in the total protein is called the degree of hydrolysis (DH). DH is a measure of the decomposition of proteins by enzymes and can be used to evaluate the properties of proteins or peptides. Studies have shown that the degree of enzymatic hydrolysis affects the biological activity of polypeptides, and different proteases produce enzymatically hydrolyzed products with different structures. In this study, four common proteases, namely alkaline protease, flavorzyme, pepsin, and trypsin, were selected to hydrolyze silkworm pupa protein, and the proteases with high enzymatic hydrolysis efficiency were screened by measuring DH. The OPA method was used in this study to determine the degree of hydrolysis of silkworm pupa protein. 400 μL of the sample solution was accurately reacted with 3 mL of the OPA solution for 2 min, and the absorbance was measured at 340 nm using a multifunctional microplate reader.
[0099] DH was calculated using the following formula:
[0100]
[0101] where h tot —— Total number of peptide bonds per protein equivalent obtained by chemical hydrolysis (h tot depends on the type of raw material and is 8.6 mmol / g in this study);
[0102] X —— Weight of the sample;
[0103] P —— Protein content of the sample;
[0104] β and α —— Depend on the type of protein;
[0105] h 0——The degree of hydrolysis of the sample relative to the original substrate before the hydrolysis reaction;
[0106] h 1 ——The degree of hydrolysis of the sample after the hydrolysis reaction relative to the original substrate.
[0107] Results: The DH of different proteases Figure 1 As shown, alkaline protease had the highest degree of hydrolysis, followed by trypsin, flavor enzyme and pepsin.
[0108] Example 3. Identification of silkworm pupa protein hydrolysate
[0109] 1. Secondary structure analysis
[0110] The present invention uses FTIR spectroscopy to analyze the secondary structure of four silkworm pupa protein hydrolysates. The sample is freeze-dried, mixed with KBr at a ratio of 1:150, and then ground into powder using a mortar. After being pressed into thin slices by a tablet press, infrared spectroscopy is performed. The wavelength range of the FTIR-650 spectrometer is set to 4000cm -1 ~400cm -1 , the number of scans is 32 times, the resolution is 4cm -1 Each sample was repeated three times under the same conditions. Curve fitting analysis was performed using Omnic 9.2 and Peak Fit v4.12.
[0111] Amide I section (1600-1700cm -1 ) is mainly based on the stretching vibration of C=O and is often used to reflect the secondary structure of proteins. The secondary structure is obtained by Gaussian curve fitting, combined with Fourier self-reflection convolution and second-order derivative. It is generally believed that the characteristic absorption peak of β-folding is 1600-1640cm -1 The characteristic absorption peak of random curl is 1640-1650cm -1 The characteristic absorption peak of α-helix is 1650-1660cm -1 The characteristic absorption peak of β-turn is 1660-1700cm -1 Generally speaking, the secondary structure of proteins is connected by various types of hydrogen bonds, among which α-helix and β-fold are relatively ordered structures. The comparison of the secondary structure content of SPP and each isolated and purified product is Figure 2 As shown, from Figure 2 It can be seen that the relative content of the secondary structure of SPPH-A has changed compared with SPP, with a decrease in the β-sheet content and an increase in the β-turn content, which may be due to the action of proteolytic enzymes, which leads to the breaking of intermolecular hydrogen bonds, the unfolding of the protein structure, and the destruction of the ordered and stable β-sheet structure, which is converted into a relatively flexible and stretched β-turn structure.
[0112] 2. Amino Acid Sequencing
[0113] The purified F3 was sequenced by LC-MS / MS. The peptide was desalted for mass spectrometry detection. The chromatographic conditions in the liquid phase included: a C18 chromatographic column (0.15 mm*150 mm, RP-C18, column Technology Inc.) was used as the chromatographic column, 0.1% formic acid aqueous solution was used as the mobile phase A, 0.1% formic acid acetonitrile aqueous solution was used as the mobile phase B, and the acetonitrile content in the mobile phase B was 84%; the liquid chromatography column was balanced with 95% A liquid; the sample was sent from the autosampler to the Zorbax 300SB-C18 peptide trap and separated on the chromatographic column; the liquid phase gradient was set as follows:
[0114] 0min-50min, linear gradient of mobile phase B from 4% to 50%, mobile phase A from 96% to 50%;
[0115] 50 min-54 min, linear gradient from 50% to 100% of mobile phase B and from 50% to 0% of mobile phase A;
[0116] 54min-60min, liquid B remains at 100%.
[0117] The present invention adopts capillary high performance liquid chromatography (HPLC) separation and Q Exactive HF-X mass spectrometer mass spectrometry (MS) analysis, the analysis time is 60min, and the detection mode is positive ion. The mass-to-charge ratio of the polypeptide and polypeptide fragments is collected as follows: 10 fragment images (MS2 scans) are collected after each full scan.
[0118] Results: A total of 609 peptides were identified. The toxicity of the peptides was first predicted based on Toxinpred (https: / / webs.iiitd.edu.in / raghava / toxinpred / multi_submit.php) and). All specific peptides were non-toxic. The peptides were then scored and screened using PeptideRanker to predict the probability that the peptides had biological activity. The higher the probability value, the greater the possibility of biological activity. Generally, the probability value > 0.8 was used for screening. Allergenicity screening was then performed on the AllerTOP Server Page, and finally these peptide sequences were searched in the BIOPEP database to screen the novelty of the peptides. A total of 9 peptides were screened, see for details. Figure 3-Figure 11 and Table 1.
[0119] Table 1 Peptide information and molecular docking obtained from F3
[0120]
[0121]
[0122] Example 4. Molecular docking
[0123] Molecular docking helps to better understand the molecular mechanism of immunomodulatory peptides. The present invention retrieves toll-like receptor proteins TLR2 (ID: 1FYW) and TLR4 / MD-2 (ID: 5IJD) from the protein database (http: / / www.rcsb.org / pdb) and downloads them, and imports them into PyMOL-2.5.2 to remove solvents and organic matter. Then, hydrogen is added using AutoDockTools-1.5.7 software, and the resulting structure is exported in the "pdbqt" format as a docking receptor. In addition, the two-dimensional structures of various polypeptides are collected from ChemDraw-20.0, imported into Chem3D-20.0 software to create a three-dimensional structure with minimized free energy, and finally exported in the "mol2" format as a docking ligand. Finally, the receptor and ligand are docked using AutoDock Vina 1.1.2 software, the binding ability is scored, and the molecular docking results are visualized using PyMOL-2.5.2.
[0124] Results: All nine peptides were successfully docked with TLR2 and TLR4 / MD-2. Binding energy is usually considered as a reference value for prediction. The smaller the binding energy, the lower the binding energy of the ligand-receptor interaction, and the easier it is to form a more stable molecular binding conformation. Generally, a binding energy ≤7Kcal / mol is considered to be a strong binding. The docking results are shown in Table 2 above. From the binding energy, all peptides have a strong binding to TLR4 / MD-2, and the cavity of TLR4 / MD-2 is large and mainly hydrophobic. These peptides can stably bind to the hydrophobic cavity and are occupied by complementary structures. Peptide 2, Peptide 3, and Peptide 8 have strong binding energies to TLR2 and TLR4 / MD-2. The binding energies of Peptide2, Peptide 3, and Peptide 8 to TLR2 are -9.3Kcal / mol, -7.2Kcal / mol, and -7Kcal / mol, respectively. The binding energies of peptide 2, peptide 3 and peptide 8 to TLR4 were -13.5Kcal / mol, -8.9Kcal / mol and -9.3Kcal / mol, respectively. Therefore, we selected these three peptides for ligand-receptor interaction site map analysis to elucidate the molecular mechanism of their immune activity.
[0125] It has been reported that the influence of hydrogen bonding interaction is greater than that of charge interaction and π-π bond interaction, and plays an important role in stabilizing the crystal structure of ligand-receptor complexes. Fig.12 As shown, the peptides bind to TLR2 and TLR4 / MD-2 primarily through hydrogen bonds and hydrophobic interactions. Fig.12 In the figure, the protein is pink and cartoon-style; the peptide is cyan and stick-shaped, and the bound amino acid residues are yellow and stick-shaped. Peptide 3 forms a binding site with HIS 697, SER-696, ASP-730, and SER-636 residues of TLR2. and Four hydrogen bonds, see Fig.12 -A. Peptide 3 forms a bond with the ILE-46 residue of TLR4 / MD-2 Long hydrogen bonds, see Fig.12 -D. Peptide 2 formed a binding site with ARG-650, TRP-764 and ARG-771 residues of TLR2 and Six hydrogen bonds, see Fig.12 -B. Peptide 2 forms a complex with the Asn-359 and LYS-360 residues of TLR4 / MD-2 and Two hydrogen bonds, see Fig.12 -E. Peptide 8 forms a binding site with ASP-678, GLU-664, ASN-688, LYS-695, and SER-692 residues of TLR2 and Eleven hydrogen bonds, see Fig.12 -C. Peptide 8 forms a binding site with LEU-94, HIS-96, ASP-101 and LYS-263 residues of TLR4 / MD-2 and Four hydrogen bonds, see Fig.12 -F. In addition to hydrogen bonds, the three peptides also bind to TLR2 and TLR4 / MD-2 via hydrophobic forces.
[0126] Example 5. Synthesis, identification and immunological activity verification of polypeptides
[0127] 1. Synthesis and identification of peptides
[0128] To determine whether Peptide 2, Peptide 3, and Peptide 8 were new sequences to be studied, we searched for these sequences on BIOPEP on July 15, 2024, but they did not appear in any publications. Then, the three peptides were synthesized by solid phase method and their immunological activity was studied. The peptides were synthesized by Shanghai Hongpeptide Biotechnology Co., Ltd. (Shanghai, China), and their purity and molecular weight were identified by HPLC and MS. Peptide 3 had a purity of 98.85% and an actual molecular weight of 984.13 Da. Peptide 2 had a purity of 99.07% and an actual molecular weight of 782.95 Da. Peptide 8 had a purity of 98.54% and an actual molecular weight of 1365.57 Da. The actual molecular weights of the three peptides were less than 0.1% of the theoretical molecular weight.
[0129] 2. Verification of the Immunoreactivity of Synthetic Peptides
[0130] Cells were treated with different concentrations of synthetic peptides. CCK8 results showed that all three synthetic peptides could promote cell growth and showed no cytotoxicity. Fig.13 -A and Fig.13 As shown in Figure 2-B, compared with the control group, the three synthetic peptides significantly promoted the proliferation and phagocytic activity of macrophages, and this increase was dose-dependent. These findings indicate that peptides extracted from silkworm pupa proteins have the potential to enhance immune regulation.
[0131] Example 6. Effects of enzymatic hydrolysis products, ultrafiltration products and separation products on macrophage immune activity indicators
[0132] Immunomodulatory peptides do not interact directly with pathogens, but promote host defense responses by binding to receptors on the surface of immune cells. Studies have reported that most amino acids with immunomodulatory effects are hydrophobic, the most common of which are glycine (Gly), valine (Val), leucine (Leu), proline (Pro), phenylalanine (Phe), the negatively charged amino acid glutamic acid (Glu), and the aromatic amino acid tyrosine (Tyr). Studies have also shown that peptides containing Ile (isoleucine) and peptides containing Ala (alanine) can promote the proliferation of immune cells and stimulate the production of immune-related immune factors. Therefore, Peptide 2, Peptide 3, and Peptide 8 bind to the active sites of TLR4 / MD-2 and TLR2 through hydrogen bonds and hydrophobic interactions, which may activate signal transduction pathways, stimulate macrophage activation, and regulate the body's immunity.
[0133] The present invention verifies the above speculation through a cellular immune activity detection experiment, and the specific method and results are as follows:
[0134] 1. Cellular immune activity detection
[0135] (1) Cell culture
[0136] RAW 264.7 cells were cultured in DMEM containing 10% fetal bovine serum and 0.5% penicillin-streptomycin in an atmosphere of 5% CO. 2 Culture in an incubator at 37°C.
[0137] (2) Cell proliferation assay
[0138] CCK-8 method was used to detect the proliferation activity of RAW264.7 cells. 5×10 4 RAW264.7 cells, 100ul suspension per well. After 12h, add 100μL of different sample solutions and incubate for 24h, with 6 replicate wells for each sample solution. After 24h, remove the culture medium and wash the wells with PBS. Another method is to use CCK8 for all viability assays. Absorbance is detected using a multifunctional microplate reader.
[0139] (3) EdU staining
[0140] To detect the effect of peptides on cell proliferation, the BeyClickTM EdU-488 imaging kit was used to measure cell proliferation according to the manufacturer's instructions and operating manual. 1 mL of RAW264.7 cell suspension (5 × 10 4 Each well was incubated for 12 h, and then 1 mL of different sample solutions was added and incubated for 24 h. The EdU staining test was performed according to the manufacturer's instructions of the BeyClickTM EdU-488 imaging kit. EdU fluorescence images were obtained using an inverted fluorescence microscope, and the percentage of EdU positively stained cells was randomly counted from three microscope fields.
[0141] (4) NO production determination
[0142] The NO production in the cell culture supernatant was detected using a Griess reaction kit. The standard was diluted according to the instructions to establish a standard curve. Macrophages (5×10 4 Each well was added to a 96-well plate containing 100 μL of culture medium and incubated at 37°C with 5% CO 2 Incubate in an incubator. After 12 hours, add 100 μL of different samples and incubate for 24 hours. Repeat 6 times for each sample. After 24 hours, take 50 μL / well of supernatant, add 50 μL of Griess Reagent I and Griess Reagent II to each well, measure the absorbance at 540 nm, and calculate the NO production using the standard curve.
[0143] (5) Phagocytic ability of macrophages
[0144] Macrophages in logarithmic growth phase were counted at 5×10 4 Each well was inoculated with 100 μL of culture medium in a 96-well plate and incubated at 37°C with 5% CO 2 Incubate in a culture incubator. After 12 hours, add 100 μL of different samples and incubate for 24 hours. Repeat 6 times for each sample. After 24 hours, remove the culture medium, wash 1-2 times with PBS, add 200 μL of cell culture medium and 20 μL of neutral red staining solution, and incubate in a cell culture incubator for 2 hours. After 2 hours, remove the culture medium, wash 1-2 times with PBS, add 200 ul of neutral red assay lysis solution, lyse on a shaker at room temperature for 10 minutes, and measure the absorbance at 540 nm.
[0145] 2. Effects of silkworm pupa protein protease hydrolysate on macrophage immune activity indicators
[0146] The relative growth rate of macrophages is one of the most commonly used indicators for evaluating immune activity. The present invention used different enzymatic hydrolysates obtained in Example 1 to treat macrophage RAW264.7. The results showed that the four enzymatic hydrolysates had no cytotoxicity to macrophages, and the alkaline protease hydrolysate (SPPH-A) could significantly promote the activation and proliferation of macrophages. Fig.14 -A.
[0147] NO is an active mediator that can play an immunomodulatory role by activating macrophages. The degree of macrophage activation can be evaluated by measuring the production of NO. Fig.14 -B shows that the NO production of SPPH-A is significantly higher than that of other components, indicating that SPPH-A can upregulate the NO production in cells. Macrophage phagocytosis is an important indicator of macrophage immune regulation. Macrophages can protect the body from infection by foreign organisms and non-biological attacks. The results of the neutral red phagocytosis experiment are shown in Fig.14 As shown in Figure 2-C, there was no significant difference in the phagocytosis rate of macrophages among the enzymatic products. These findings suggest that SPPH-A may be a potential regulator of immune activity, so we focused on SPPH-A to identify the key functional peptides.
[0148] 3. Effect of ultrafiltration products on macrophage immune activity indicators
[0149] In order to identify the key functional peptides of SPPH-A, the present invention further purified the protease hydrolysate of silkworm pupa protein. SPPH-A was dissolved in ultrapure water at a concentration of 1 mg / mL, and was divided into three components by different ultrafiltration membranes, named SPPH-A-Ⅰ (>10KDa), SPPH-A-Ⅱ (10-3KDa) and SPPH-A-Ⅲ (<3KDa). The immune activity of each component was determined by macrophage proliferation, phagocytosis and NO production, and the strongest component was screened out. The results showed that compared with the control group, SPPH-A-III significantly stimulated the activation, proliferation and phagocytosis of macrophages, see for details. Fig.15 This suggests that SPPH-A-III contains active peptides that activate the immune activity of RAW 264.7 cells. Consistent with previous studies, low molecular weight peptides generally have better activity.
[0150] 4. Effect of separation products on macrophage immune activity indicators
[0151] In order to identify the fraction with stronger immunoreactivity, SPPH-A-III was separated into three fractions using a Sephadex G-25 packed size exclusion chromatography column, such as Fig.16 As shown, the effects of the three parts on macrophage proliferation, NO production and phagocytosis were determined. The results showed that compared with the control group, F3 significantly stimulated the activation and proliferation of macrophages, NO production and phagocytosis, as shown in Fig.17 In addition, EdU staining was used to evaluate the proliferation level of cells. The results showed that the percentage of edu-positive cells in cells incubated with F3 increased significantly compared with the control group. Fig.18 This indicates that F3 has higher immunoreactivity and contains more active peptides that activate the immune activity of RAW 264.7 cells.
Claims
1. Silkworm pupa protein immunomodulatory peptide, characterized in that: The silkworm pupa protein immunomodulatory peptide contains the amino acid sequence shown in SEQ ID NO.2, SEQ ID NO.3 and / or SEQ ID NO.
8.
2. The silkworm pupa protein immunomodulatory peptide according to claim 1, characterized in that: The amino acid sequence of the silkworm pupa protein immunomodulatory peptide is shown as SEQ ID NO.2, SEQ ID NO.3 or SEQ ID NO.
8.
3. A method for preparing a silkworm pupa protein immunomodulatory peptide, characterized in that: The steps include: (1) Using defatted silkworm pupa powder as raw material to prepare silkworm pupa protein; (2) hydrolyzing the silkworm pupa protein obtained in step (1) with alkaline protease to obtain silkworm pupa protein hydrolysate; (3) The silkworm pupa protein hydrolysate obtained in step (2) is separated and purified by ultrafiltration and gel filtration to obtain a separated product; (4) performing LC-MS / MS sequencing on the separated product obtained in step (3) to obtain the silkworm pupa protein immunomodulatory peptide.
4. The method according to claim 3, characterized in that In step (2), the enzymatic hydrolysis conditions are: pH 7-9, temperature 40°C-60°C, and time 2h-5h.
5. The method according to claim 3, characterized in that: In step (2), the amount of alkaline protease used is 5000U / g-10000U / g.
6. The method according to claim 3, characterized in that In step (2), NaOH is continuously added during the hydrolysis process to maintain the pH.
7. The method according to claim 3, characterized in that The liquid phase of the LC-MS / MS is a C18 chromatographic column, with formic acid aqueous solution as mobile phase A and formic acid acetonitrile aqueous solution as mobile phase B, and separation is performed by gradient elution; after separation, analysis is performed by a mass spectrometer; the gradient elution program is set as follows: 0 min-50 min, linear gradient of mobile phase B from 4% to 50%, mobile phase A from 96% to 50%; 50 min-54 min, linear gradient from 50% to 100% mobile phase B and from 50% to 0% mobile phase A; 54min-60min, liquid B remains at 100%.
8. Use of the silkworm pupa protein immunomodulatory peptide according to any one of claims 1 to 2 in the preparation of products for enhancing body immunity.
9. The use according to claim 8, characterized in that: The product includes any one or more of functional food, dietary supplement, medicine, skin care product, and cosmetics.
10. Use of the silkworm pupa protein immunomodulatory peptide according to any one of claims 1 to 2 in the preparation of a promoter for promoting macrophage proliferation, phagocytosis and / or NO production.
Citation Information
Patent Citations
Silkworm chrysalis immune peptide as well as preparation method and application thereof
CN115232851A
Anticancer active peptide BPP-3 of silkworm pupa as well as preparation method and application of anticancer active peptide BPP-3
CN109182429A
Cicada pupa protein, cicada pupa polypeptide and preparation method and application thereof
CN117024510A
Cited By
Active superantigen immune reconstitution compound biological injection preparation A and its preparation method
CN119770634A
Immunopotentiator containing high-activity microbial protein peptide and preparation method of immunopotentiator
CN121003690A
